Report
EUR 12.77 For Business Accounts Only

INSPIRE MEDICAL SYSTEMS sees an upgrade to Slightly Negative thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to INSPIRE MEDICAL SYSTEMS (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date February 8, 2022, the closing price was USD 233.71 and its target price was estimated at USD 166.87.
Underlying
Inspire Medical Systems

Inspire Medical Systems is a medical technology company focused on the development and commercialization of solutions for patients with obstructive sleep apnea. The company's proprietary Inspire system is the United States Food and Drug Administration-approved neurostimulation technology that provides a treatment for moderate to severe obstructive sleep apnea. The company has developed a solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company sells its Inspire system to hospitals and ambulatory surgery centers in the United States and in select countries in Europe through a direct sales organization.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch